Study to Evaluate Efficacy of LAI When Added to Multi-drug Regimen Compared to Multi-drug Regimen Alone

NCT02344004 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

336

Enrollment

INDUSTRY

Sponsor class

Conditions

Mycobacterium Infections, Nontuberculous

Interventions

DRUG: LAI (Liposomal Amikacin for Inhalation) 590 mg

Sponsor

Insmed Incorporated